학술논문
43766 Cumulative clinical benefit over 52 weeks comparing initiation with deucravacitinib versus apremilast in patients with moderate to severe plaque psoriasis: a post hoc analysis of POETYK PSO-1 trial results stratified by prior treatment
Document Type
Abstract
Author
Source
In Journal of the American Academy of Dermatology September 2023 89(3) Supplement:AB30-AB30
Subject
Language
ISSN
0190-9622